2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2715 Treatment landscape and survival outcomes among patients treated for mantle cell lymphoma in real-world practice

Krish Patel, MD, Narendranath Epperla, MD, MS, FACP2, Xiaoliang Wang3, Christina Chandra4, Anthony Proli, PharmD5, Matt Bye6, Matthew Pesavento7, Gregory S Maglinte8, Derrick Van Beuge9, Erlene K. Seymour, MD10, Javier L. Munoz, MD, MBA11, Yucai Wang, MD, PhD12
1 Sarah Cannon Research Institute, Nashville, Tennessee, United States
2 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
3 BeOne Medicines, Ltd, San Carlos, California, United States
4 Flatiron Health, New York, New York, United States
5 Flatiron Health, New York, New York, United States
6 Flatiron Health, New York, New York, United States
7 Flatiron Health, New York, New York, United States
8 BeOne Medicines, Ltd, San Carlos, California, United States
9 BeOne Medicines, Ltd, San Carlos, California, United States
10 BeOne Medicines, Ltd, San Carlos, California, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Mantle cell lymphoma (MCL) is a rare, aggressive and incurable B-cell non-Hodgkin lymphoma. Although chemoimmunnotherapy (CIT) remains common frontline treatment (tx), use of covalent Bruton kinase inhibitors (cBTKis) has increased substantially. Despite these advances, outcomes after cBTKi discontinuation remain suboptimal and subsequent tx options are limited. This study examined real-world tx patterns across multiple lines of therapy (LOTs) and assessed clinical outcomes in patients (pts) with MCL.

Methods: This retrospective cohort study used the electronic health record-derived, deidentified Flatiron Health Research Database and included adults diagnosed with MCL who initiated 1L between 2016-2025. Pts were followed from 1L initiation until last activity, death, or study end (03/31/2026). Tx patterns were summarized by LOT (1-4L) overall and by 1L subgroup (aggressive [cytarabine-containing] vs less aggressive induction tx per NCCN guidelines). Real-world time to next tx (rwTTNT) and overall survival (rwOS), were assessed using Kaplan-Meier methods for 1L overall, by 1L subgroup, and in the post-cBTKi subgroup.

Results: A total of 4674 pts were included (median age at 1L: 70 years [IQR: 63-77]; 72% male); 2490 pts had stage IV MCL (53%); TP53 mutations via NGS were tested in 19% (n=906) before 1L, with 25% (n=222) positive among those tested. 3171 pts (68%) had Ki67 data before 1L, with 48% (n=1513) had Ki67 ≥30% among those tested. Median follow-up was 27 months (IQR: 9-54). 491 (11%) received aggressive 1L therapy (median age at 1L: 61 years [IQR: 55-66]), 3125 (67%) received less aggressive 1L therapy (71 years [IQR: 64-77]). Remaining pts received clinical study drug (4%), lenalidomide +/- rituximab (3%), anti-CD20 monotherapy (8.9%), or other therapy (3.5%).

In 1L, CIT was the most frequent tx (67%), predominantly bendamustine and rituximab (BR; 45% of all 1L), followed by cBTKi-based regimens (13%). Rituximab maintenance was administered to 37% of pts treated with 1L BR. In later lines (2L+), cBTKi monotherapy was the most common regimen (31% in 2L, 20% in 3L, and 13% in 4L), followed by CIT (21%, 15%, and 11%, respectively). Venetoclax-based, pirtobrutinib, and CAR –T-cell therapies were used more frequently in 3-4L (range 5-10%). Autologous stem cell transplant as consolidation after 1L was received by 9% and was more common among those receiving aggressive 1L therapy (38% vs 6%). Tx patterns were similar across 2-4L regardless of 1L intensity.

Overall median rwTTNT was 20 months (95% confidence interval [CI]: 19-22) from 1L. Median rwTTNT was 27 months (95% CI: 20-37) in pts treated with aggressive 1L therapy, and 24 months (95% CI: 22-27) in pts with less aggressive 1L therapy. Overall median rwOS was 71 months (95% CI: 67-75), with 24-months OS rates of 76% (74-77%). Median rwOS was 112 months (95% CI: 107-NR) among pts who received aggressive 1L therapy, and 68 months (95% CI: 64-74) for those with less aggressive 1L therapy.

In the post-cBTKi subgroup (n=839), median age at post-cBTKi therapy start was 71 years (IQR: 63-78); 71% male and 63% were treated in community care. TP53 was tested in 33% pts (n=275), with 42% positive among pts tested; 74% pts (n=625) had Ki67 results, with 20% had Ki67 30-49% and 44% had Ki67 ≥50%. Median follow-up from initiation of post-cBTKi therapy was 10 months (IQR: 3-26). Post-cBTKi therapy occurred in 3L for 50% (n=421) of pts, 2L for 31% (n=261), and 4L for 14% (n=119). The most common post-cBTKi therapies were cBTKi-containing regimens (36%), mainly with anti-CD20 therapy (19%) or BCL2 inhibitors (12%). CIT was used in 15%, pirtobrutinib-containing regimens in 11%, and CAR T-cell therapy in 8%. Median rwTTNT was 6 months (95% CI: 6-7), and median rwOS was 27 months (95% CI: 23-31). Outcomes decreased as index line increased (rwTTNT: 8 months at 2L; 6 months at 3L; rwOS: 37 months at 2L; 23 months at 3L).

Conclusions: In this real-world analysis, 1L tx of MCL remained dominated by BR and approximately one-third of pts received rituximab maintenance. The use of cBTKis in 1L is increasing and continues to be widely used across subsequent LOT. Longer survival with intensive frontline therapy likely reflects favorable baseline characteristics. Despite outcomes that compare favorably with historical post-BTKi benchmarks, therapeutic options following cBTKi exposure remained limited, highlighting an unmet need for effective txs.

Krish Patel, MD: Kite - Honoraria; Pfizer - Honoraria; ADC Therapeutics - Honoraria; Lilly - Honoraria; Genentech/Roche - Honoraria; Merck - Honoraria; BeiGene - Honoraria; Bristol-Myers Squibb - Honoraria; AbbVie - Honoraria; AstraZeneca - Honoraria; Caribou Biosciences - Honoraria; Fate Therapeutics - Research Funding; Nurix - Research Funding; Mittenyi Biomedicine - Research Funding; Bristol-Myers Squibb - Research Funding; Pfizer - Research Funding; AvenCell - Research Funding; AstraZeneca - Research Funding; Immunome - Research Funding; Kite - Research Funding; MEI Pharma - Research Funding; Merck - Research Funding; Janssen - Research Funding; Xencor - Research Funding; Sana Biotechnology - Research Funding; Genentech/Roche - Research Funding; Pharmacyclics - Research Funding; Indapta Therapeutics - Research Funding; Lilly - Research Funding; Arvinas - Research Funding; Treeline Biosciences - Research Funding; Ono Pharmaceutical - Research Funding; CRISPR Therapeutics - Research Funding; Loxo Oncology - Research Funding; AbbVie - Research Funding; Lyell Immunopharma - Research Funding; Umoja Biopharma - Research Funding; TORL Biotherapeutics - Research Funding; Adicet - Research Funding; Adaptive Biotechnologies - Research Funding; Bristol-Myers Squibb - Consultancy (Includes expert testimony); Foresight Diagnostics - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); BioNTech - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Lyell Immunopharma - Consultancy (Includes expert testimony); Avencell Therapeutics - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Century Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Kyverna Therapeutics - Consultancy (Includes expert testimony); Immunome - Consultancy (Includes expert testimony); Arcus Biosciences - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); AvenCell - Consultancy (Includes expert testimony); BicycleTx - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)